• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502
• 3. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 4. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 5. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696

Introduction to 5,5-dimethyl-decahydroisoquinoline (CAS No. 1820604-49-6)

5,5-dimethyl-decahydroisoquinoline, identified by the Chemical Abstracts Service Number (CAS No.) 1820604-49-6, is a heterocyclic organic compound belonging to the decahydroisoquinoline family. This molecule has garnered significant attention in the field of pharmaceutical chemistry and medicinal biology due to its unique structural framework and potential biological activities. The presence of two methyl groups at the 5-position of the isoquinoline ring system imparts distinct electronic and steric properties, making it a valuable scaffold for drug discovery and synthetic chemistry.

The decahydroisoquinoline core is a common motif in natural products and pharmacologically active compounds. Its aromaticity, coupled with the flexibility of the saturated ring system, allows for diverse functionalization and interaction with biological targets. In recent years, 5,5-dimethyl-decahydroisoquinoline has been explored as a key intermediate in the synthesis of more complex molecules with therapeutic potential. Its structural analogs have shown promise in various preclinical studies, particularly in modulating enzymatic pathways and receptor binding affinities.

One of the most compelling aspects of 5,5-dimethyl-decahydroisoquinoline is its role as a building block in the development of novel bioactive entities. Researchers have leveraged its scaffold to create derivatives with enhanced pharmacokinetic profiles and improved target specificity. For instance, modifications at the 3- and 7-positions of the decahydroisoquinoline ring have led to compounds with significant activity against certain kinases and transcription factors. These findings underscore the importance of 5,5-dimethyl-decahydroisoquinoline in medicinal chemistry and highlight its potential as a lead compound or intermediate in future drug development pipelines.

The synthesis of 5,5-dimethyl-decahydroisoquinoline typically involves multi-step organic transformations, often starting from readily available precursors such as benzaldehyde derivatives or amino acids. Advances in catalytic methods have enabled more efficient routes to this compound, reducing both reaction times and waste generation. For example, palladium-catalyzed cross-coupling reactions have been employed to construct the isoquinoline core with high regioselectivity. Such improvements not only facilitate large-scale production but also align with green chemistry principles by minimizing hazardous byproducts.

Recent studies have also explored the computational modeling of 5,5-dimethyl-decahydroisoquinoline derivatives to predict their binding modes and efficacy against disease-related targets. Molecular dynamics simulations and quantum mechanical calculations have provided insights into how structural modifications influence bioactivity. These computational approaches complement experimental efforts by allowing rapid screening of virtual libraries before synthesizing candidate compounds. Such interdisciplinary strategies are critical for accelerating the discovery of novel therapeutics based on decahydroisoquinoline scaffolds.

The pharmacological profile of 5,5-dimethyl-decahydroisoquinoline has been investigated across multiple disease models. Preclinical data suggest that certain analogs exhibit anti-inflammatory properties by inhibiting key signaling pathways involved in immune responses. Additionally, their ability to modulate neurotransmitter receptors has opened avenues for research into neurological disorders. While further clinical trials are needed to validate these effects in humans, these preliminary findings highlight the therapeutic promise of this chemical class.

In conclusion,5,5-dimethyl-decahydroisoquinoline (CAS No. 1820604-49-6) represents a fascinating compound with broad applications in pharmaceutical research. Its unique structural features make it an ideal candidate for generating structurally diverse libraries for high-throughput screening. As synthetic methodologies continue to evolve and computational tools become more sophisticated,decahydroisoquinoline derivatives will remain at the forefront of drug discovery efforts aimed at addressing unmet medical needs.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)